/NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S.
WIRE SERVICES/
WINNIPEG, Dec. 7, 2017 /CNW/ - DELTA 9 CANNABIS INC. (TSXV:
NINE) ("Delta 9" or the "Company") is pleased to announce that it
has entered into an agreement with a syndicate of underwriters led
by Canaccord Genuity Corp. (the "Underwriters") pursuant to which
the Underwriters have agreed to purchase, on a bought deal basis
pursuant to the filing of a short form prospectus, an aggregate of
7,410,000 units (the "Units") at a price of $2.70 per Unit (the "Offering Price") for
aggregate gross proceeds to the Company of $20,007,000 (the "Offering").
Each Unit will consist of one common share of the Company (a
"Common Share") and one Common Share purchase warrant (each whole
Common Share purchase warrant, a "Warrant"). Each Warrant will be
exercisable to acquire one Common Share (a "Warrant Share") for a
period of 30 months following the closing of the Offering (the
"Closing") at an exercise price of $3.25 per Warrant Share.
The Company has granted the Underwriter an option (the
"Over-Allotment Option"), to purchase up to an additional 1,111,500
Units at a price of C$2.70 per Unit,
exercisable at any time, for a period of 30 days after and
including the Closing Date. The Over-Allotment Option is
exercisable to acquire Units, Common Shares and/or Warrants (or any
combination thereof) at the discretion of the Underwriter.
The net proceeds of the Offering will be used to for expansion
capital expenditures and general corporate purposes.
The Units will be offered by way of a short form prospectus to
be filed in all provinces of Canada except Quebec. The Offering is expected to close on
December 28, 2017 and is subject to
certain conditions including, but not limited to, the receipt of
all necessary regulatory and stock exchange approvals, including
the approval of the TSX Venture Exchange and the applicable
securities regulatory authorities.
The securities being offered have not been, nor will they be,
registered under the United States Securities Act of 1933, as
amended, and may not be offered or sold in the United States or to, or for the account or
benefit of, U.S. persons absent registration or an applicable
exemption from the registration requirements. This news release
will not constitute an offer to sell or the solicitation of an
offer to buy nor will there be any sale of the securities in any
state in which such offer, solicitation or sale would be
unlawful.
About Delta 9 Cannabis Inc.
Delta 9's wholly-owned
subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of
medical marijuana pursuant to the ACMPR and operates an 80,000
square foot production facility in Winnipeg, Manitoba, Canada. Delta 9's shares
trade on the TSX Venture Exchange under the symbol "NINE".
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this release are forward-looking
statements, which reflect the expectations of management regarding
the Company's future business plans and other matters.
Forward-looking statements consist of statements that are not
purely historical, including any statements regarding beliefs,
plans, expectations or intentions regarding the future. Forward
looking statements in this news release include statements relating
to the closing of the Offering and the use of proceeds of the
Offering. Such statements are subject to risks and uncertainties
that may cause actual results, performance or developments to
differ materially from those contained in the statements, including
that Delta 9's currently contemplated expansion and development
plans may cease or otherwise change, Delta 9's production of
cannabis may be lower than expected, Delta 9 may not obtain the
required approvals from Health Canada, demand for Delta 9's
products may be lower than anticipated, Delta 9's cost to produce
its grow pods may be higher than expected and all other risk
factors set forth in the filing statement of Delta 9 dated
October 25, 2017 which has been filed
on SEDAR. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if
they do occur, what benefits the Company will obtain from them.
Readers are urged to consider these factors carefully in evaluating
the forward-looking statements contained in this news release and
are cautioned not to place undue reliance on such forward-looking
statements, which are qualified in their entirety by these
cautionary statements. These forward-looking statements are made as
of the date hereof and the Company disclaims any intent or
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or results or
otherwise, except as required by applicable securities laws.
SOURCE Delta 9 Cannabis Inc.